The Oral Peptide Breakthroughs of 2026: The Wegovy Pill, Icotrokinra and Enlicitide
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- Three peptide medicines for common conditions now come as tablets: semaglutide tablets for weight (Wegovy), icotrokinra for psoriasis (Icotyde) and enlicitide for LDL cholesterol (Lipfendra) 2 4 3.
- Each absorbs only a sliver of its dose: about 1% to 2% for semaglutide tablets and about 1% for enlicitide, against 89% for semaglutide injected 2 3.
- They work anyway because of engineering: an absorption enhancer (SNAC) for semaglutide; a peptide that binds its receptor at 7 picomolar for icotrokinra; and for enlicitide a macrocyclic peptide binding at about 5 picomolar, with sodium caprate to help absorption 5 4 9 3.
- The price of the pill is strict rules: an empty stomach, water (or, for enlicitide, black coffee or plain tea), and 30 minutes before food 2 4 3. For the research peptides sold as capsules, we found no published human study measuring how much reaches the blood.
Why peptides have needed needles
A peptide is a short chain of amino acids, and the digestive system exists to take such chains apart. Swallowed, a peptide meets stomach acid and digestive enzymes, then a mucus layer and an intestinal lining that lets large, water-loving molecules through only poorly. A 2020 review in Nature Reviews Drug Discovery sets out the barriers and the tricks tried against them, from permeation enhancers and enzyme inhibitors to cell-penetrating peptides, and traces decades of attempts with insulin, calcitonin, parathyroid hormone and vasopressin before oral semaglutide was approved for type 2 diabetes.1
The numbers explain why injection has been the default. Semaglutide injected under the skin reaches the circulation almost completely: its absolute bioavailability is 89%. Swallowed as a tablet, the figure is about 1% to 2%.2 Enlicitide, the new cholesterol pill, is also about 1%.3 Icotrokinra's label gives no bioavailability figure.4 Each of the three needed a specific piece of engineering, described below, and each comes with instructions about food and timing.2 4 3
The Wegovy pill: semaglutide and SNAC
Wegovy tablets contain semaglutide co-formulated with salcaprozate sodium, known as SNAC, which the label calls an absorption enhancer.2 How it works was studied in people and dogs: absorption happens in the stomach, not the intestine, in a small area close to the dissolving tablet, and only when SNAC is present. SNAC buffers the acid around the tablet, which protects semaglutide from digestive enzymes, and briefly helps it cross the stomach lining through the cells themselves, without loosening the junctions between them.5
That mechanism explains the label's rules. The tablet is taken once a day on an empty stomach in the morning with no more than 4 ounces of plain water, swallowed whole, and followed by at least 30 minutes without food, other drinks or other oral medicines.2 The dose shows the cost of 1% absorption: the top tablet dose is 25 mg a day, about 73 times as much semaglutide each week as the 2.4 mg weekly injection.2
It works. In the 64-week trial behind the tablet's weight indication, 307 adults with obesity or overweight lost 13.6% of their weight on the 25 mg tablet against 2.4% on placebo, and 47% of those on the tablet lost at least 15%.2 The label also warns that blood levels vary more with tablets than with the injection, and that some people with type 2 diabetes may not reach therapeutic levels on tablets.2
Icotrokinra: an oral peptide for psoriasis
FDA approved Icotyde (icotrokinra) on March 17, 2026, for moderate-to-severe plaque psoriasis in adults and in children 12 and older who weigh at least 40 kg, on four trials involving 2,500 people at 496 sites in 17 countries.6 The drug is a peptide that binds the interleukin-23 receptor with a dissociation constant of 7 picomolar and blocks the cytokine that drives psoriatic inflammation, the same pathway targeted by monoclonal antibodies against interleukin-23, which must be injected.4 7 The dose is one 200 mg tablet a day, taken with water on waking, on an empty stomach, with 30 minutes before food; a high-fat meal cut its absorption by 43%.4
In ICONIC-LEAD, 684 adults and adolescents were randomised 2:1. At 16 weeks, 65% on icotrokinra had clear or almost clear skin against 8% on placebo, and 50% against 4% had a 90% improvement in their psoriasis score; adverse events were reported by 49% in both groups.8 In ICONIC-ADVANCE 1 and 2, icotrokinra also beat deucravacitinib, an existing oral psoriasis drug: in the first trial 68% reached clear or almost clear skin at 16 weeks against 11% on placebo, and the authors report superior response rates against both placebo and deucravacitinib.7 The label's warnings concern infections, including tuberculosis, and live vaccines.4
Enlicitide: a macrocyclic peptide for cholesterol
Enlicitide was designed to be swallowed. Its developers used mRNA display, a screening method that searches huge libraries of peptides, to find a lead, then optimised it into a macrocyclic peptide, a ring-shaped molecule, that binds PCSK9 with an affinity of about 5 picomolar. In its first human studies, 20 mg once daily for 14 days lowered LDL cholesterol by up to 61% in people already taking statins.9 PCSK9 binds the LDL receptors on liver cells and promotes their breakdown; blocking that binding leaves more receptors to clear LDL from the blood.3 Injected antibodies and an siRNA already lower LDL cholesterol through the same protein, and as of 2023 no oral PCSK9 inhibitor was available despite nearly two decades of effort.9
FDA approved Lipfendra on July 15, 2026, to reduce LDL cholesterol.10 It is taken as one 20 mg tablet each morning on an empty stomach with water, black coffee or plain tea, swallowed whole, with 30 minutes before food; the label says each tablet contains sodium caprate, which facilitates the absorption of enlicitide, and gives its bioavailability as about 1%.3 In CORALreef Lipids, 2,909 people (intention-to-treat population) with atherosclerotic disease or at risk of it, who needed further LDL lowering despite stable lipid-lowering treatment, were randomised 2:1 to enlicitide or placebo: LDL cholesterol fell 57.1% on enlicitide and rose 3.0% on placebo over 24 weeks, a difference of 55.8 percentage points, and adverse events did not appear to differ.11
Why 1% can be enough
The three drugs point to the same lesson. A peptide that is absorbed poorly can still work if it is potent enough, or if enough of it is swallowed. Icotrokinra and enlicitide bind their targets at picomolar concentrations (7 pM and about 5 pM), and enlicitide's tablet also carries sodium caprate to help absorption.4 9 3 Semaglutide tablets take the other route: a far larger dose, carried across by SNAC.2 5 All three come with rules about timing and food, and for semaglutide the label reports more variation in blood levels with tablets than with the injection.2 4 3
Why most peptides still can't be swallowed
None of this makes peptides in general oral. The approved tablets are specific molecules with specific formulations, tested for how much of each dose reaches the blood. Semaglutide without SNAC is not absorbed meaningfully from the stomach at all.5 For the research peptides sold as capsules or "oral" versions of injectable compounds, we have found no published human study measuring how much reaches the circulation; a capsule of a peptide that has never been tested this way is a guess about absorption, however it is labelled.
Oral does not always mean peptide, either. Foundayo (orforglipron), approved in 2026 as a daily pill that activates the GLP-1 receptor, is a small molecule, not a peptide.12 13 Our encyclopedia marks every entry's molecule class, and the entries for semaglutide and orforglipron show the difference.
What it means if you take one
For the conditions they treat, the pills are a real choice where only injections existed. The choice comes with conditions. Each is taken once a day on an empty stomach with a 30-minute wait before food, and food can reduce what is absorbed: a high-fat meal cut icotrokinra's exposure by 43%.2 4 3 For semaglutide, blood levels vary more with tablets than with the injection, and for people with type 2 diabetes who respond inadequately to the tablets the label says to consider alternatives, including switching to the injection.2 Our GLP-1 drug interactions guide covers what else the tablets interact with, including levothyroxine.
Frequently asked questions
Can peptides be taken as pills?
Some now can. Semaglutide (Wegovy tablets), icotrokinra (Icotyde) and enlicitide (Lipfendra) are approved as tablets. Semaglutide tablets absorb about 1% to 2% of the dose and enlicitide about 1% (icotrokinra's label gives no figure), and each has strict dosing rules. Most peptides are still injected.
Why do oral peptides have to be taken on an empty stomach?
Food and other drinks reduce how much of a poorly absorbed peptide gets into the blood. Icotyde's absorption fell 43% after a high-fat meal, and all three labels require at least 30 minutes before eating.
Is the Wegovy pill as effective as the injection?
In its 64-week trial the 25 mg tablet produced 13.6% weight loss against 2.4% on placebo. The label notes blood levels vary more with tablets and, for people with type 2 diabetes who respond inadequately, says to consider alternatives including the injection. In people without type 2 diabetes, the label predicts the 25 mg tablet's average blood levels to be comparable to the 2.4 mg weekly injection's, with more variation.
What is SNAC?
Salcaprozate sodium, the absorption enhancer in semaglutide tablets. It buffers stomach acid around the tablet, protecting semaglutide from enzymes, and briefly helps it cross the stomach lining.
Are oral or capsule forms of research peptides absorbed?
We have found no published human study measuring how much of any capsule research peptide, such as BPC-157, reaches the blood. The approved oral peptides each needed specific engineering and testing to show absorption.
Related on Grey Peptides
- Semaglutide vs tirzepatide
- GLP-1 drug interactions
- Semaglutide encyclopedia entry
- Orforglipron encyclopedia entry
- Compound explorer (filter by molecule class)
- GLP-1 transition hub
Sources
- Drucker, D. J. (2020). Advances in oral peptide therapeutics. Nature Reviews Drug Discovery, 19(4), 277-289. PMID: 31848464 · doi:10.1038/s41573-019-0053-0
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, US prescribing information: tablets co-formulated with SNAC, an absorption enhancer; absorption predominantly in the stomach; absolute bioavailability about 1% to 2% for tablets and 89% for injection; administration (empty stomach, up to 4 oz water, 30 minutes); Study 7 (307 patients, 64 weeks, 25 mg tablet -13.6% vs -2.4%); variability and switching advice. DailyMed set ee06186f, version 19, effective June 18, 2026 (current on DailyMed October 27, 2026); read October 27, 2026. DailyMed
- Merck Sharp & Dohme. LIPFENDRA (enlicitide decanoate) tablets, US prescribing information: macrocyclic peptide PCSK9 inhibitor (section 12.1: PCSK9 binds hepatocyte LDL receptors and promotes their degradation); 20 mg once daily on an empty stomach with water, black coffee or plain tea, 30 minutes before food; each tablet contains sodium caprate, which facilitates the oral absorption of enlicitide; oral bioavailability approximately 1%. DailyMed set 100ec543, version 2, effective July 15, 2026 (current on DailyMed October 27, 2026); read October 27, 2026. DailyMed
- Janssen Biotech. ICOTYDE (icotrokinra) tablets, US prescribing information: IL-23 receptor antagonist peptide (dissociation constant 7 pM, section 12.1); no bioavailability figure given; 200 mg once daily on an empty stomach upon waking, 30 minutes before food; high-fat meal reduced AUC by 43% and Cmax by 59%; warnings for infections, tuberculosis and live vaccines. DailyMed set aee3c963, version 2, effective March 17, 2026 (current on DailyMed October 27, 2026); read October 27, 2026. DailyMed
- Buckley, S. T. et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. PMID: 30429357 · doi:10.1126/scitranslmed.aar7047
- U.S. Food and Drug Administration. Drug Trials Snapshots: ICOTYDE (original approval date March 17, 2026; four trials, 2,500 subjects, 496 sites in 17 countries; content current as of August 11, 2026). Read October 27, 2026. FDA
- Gold, L. S. et al. (2025). Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet, 406(10510), 1363-1374. PMID: 40976249 · doi:10.1016/S0140-6736(25)01576-4
- Bissonnette, R. et al. (2025). Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. New England Journal of Medicine, 393(18), 1784-1795. PMID: 41191940 · doi:10.1056/NEJMoa2504187
- Johns, D. G. et al. (2023). Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation, 148(2), 144-158. PMID: 37125593 · doi:10.1161/CIRCULATIONAHA.122.063372
- U.S. Food and Drug Administration. Novel Drug Approvals for 2026 (Lipfendra, enlicitide decanoate, approved July 15, 2026; content current as of October 20, 2026). Read October 27, 2026. FDA
- Navar, A. M. et al. (2026). A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine, 394(6), 529-539. PMID: 41879224 · doi:10.1056/NEJMoa2511002
- Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, US prescribing information: a GLP-1 receptor agonist tablet taken once daily; Initial U.S. Approval 2026 (FDA Novel Drug Approvals: April 1, 2026). DailyMed set 8ac446c5, version 10, effective July 29, 2026 (current on DailyMed October 27, 2026); read October 27, 2026. DailyMed
- Wharton, S. et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine, 393(18), 1796-1806. PMID: 40960239 · doi:10.1056/NEJMoa2511774
This article explains how three approved medicines work and what their labels and trials report. It is not medical advice; whether a pill or an injection suits a person is a decision for their prescriber.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead